Aegerion Pharmaceuticals Inc., of Cambridge, Mass., said it recorded $51.7 million in net product sales of Juxtapid (lomitapide) capsules in the fourth quarter of 2014, representing growth of approximately 111 percent over the fourth quarter of 2013.